Head of Research, IPOs & Placements, Aequitas Research

Sumeet Singh

Head of Research, IPOs & Placements

IPOs and Placements coverage across Asia Pacific

Aequitas Research

We cover all listing across the Asia Pacific along with follow-up placements. As of Dec 2020, our team had covered 539 IPOs with a hit rate of 73.5% and 685 placements with a hit rate of 66.8%.

We combine fundamental bottom-up views with our proprietary quantitative framework to provide a holistic coverage across new listings and placements. Our coverage includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/mirxes-holding-company-limited" target="_blank" data-smartkarma-citation="entities:39971:1" rel="noopener">Mirxes Holding (2629 HK)</a> raised around US$130m in its Hong Kong listing in May 2025. The lockup on its pre-IPO shareholders is set to expire soon.</li>
<li>Mirxes is a Singapore-headquartered micro ribonucleic acid (miRNA) technology company, making diagnostic solutions for the screening of diseases accessible across key markets in Asia, including Singapore and China.</li>
<li>In this note, we will talk about the lockup dynamics and possible placement.</li>
</ul>



Mirxes Holding (2629 HK) raised around US$130m in its Hong Kong listing in May 2025. The lockup on its pre-IPO shareholders is set to expire soon.
Mirxes is a Singapore-headquartered micro ribonucleic acid (miRNA) technology company, making diagnostic solutions for the screening of diseases accessible across key markets in Asia, including Singapore and China.
In this note, we will talk about the lockup dynamics and possible placement.


Aequitas: Mirxes IPO Lockup - 44% of the Stock up for Lockup Release, with a Lot of CCASS Movement

Global Healthcare Analyst

Tina Banerjee

Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/cspc-pharmaceutical-group-ltd" target="_blank" data-smartkarma-citation="entities:229:1" rel="noopener">CSPC Pharmaceutical Group (1093 HK)</a> entered into a strategic collaboration and license agreement with AstraZeneca for the development of innovative long-acting peptide medicines.</li>
<li>CSPC will receive upfront payment of US$1.2B and will be eligible for US$3.5B in R&amp;D milestone payments, US$13.8B in sales milestone payments, plus up to double-digit royalties.</li>
<li>CSPC’s play in the weight management drug scene will surely help boost revenues, but intense competition is likely to make the party short lived.</li>
</ul>



CSPC Pharmaceutical Group (1093 HK) entered into a strategic collaboration and license agreement with AstraZeneca for the development of innovative long-acting peptide medicines.
CSPC will receive upfront payment of US$1.2B and will be eligible for US$3.5B in R&amp;D milestone payments, US$13.8B in sales milestone payments, plus up to double-digit royalties.
CSPC’s play in the weight management drug scene will surely help boost revenues, but intense competition is likely to make the party short lived.


CSPC Pharma (1093 HK): AstraZeneca Collaboration Good, Impact Might Be Short Lived Given Competition

Simcere Pharmaceutical / Equity Bottom-Up

<ul>
<li>
<a href="https://www.smartkarma.com/entities/simcere-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:29186:1" rel="noopener">Simcere Pharmaceutical Group (2096 HK)</a> proposed to spin-off and separately list the shares of Simcere Zaiming, a subsidiary of the company.</li>
<li>Following the completion of the proposed spin-off, Simcere Pharma will have an interest of over 50% in Simcere Zaiming and Zaiming will remain as a subsidiary of the company.</li>
<li>We feel this is a sort of value unlocking and also simultaneously allowing Simcere Zaiming, as an independently listed entity, access to funds for R&amp;D and future growth.  </li>
</ul>



Simcere Pharmaceutical Group (2096 HK) proposed to spin-off and separately list the shares of Simcere Zaiming, a subsidiary of the company.
Following the completion of the proposed spin-off, Simcere Pharma will have an interest of over 50% in Simcere Zaiming and Zaiming will remain as a subsidiary of the company.
We feel this is a sort of value unlocking and also simultaneously allowing Simcere Zaiming, as an independently listed entity, access to funds for R&amp;D and future growth.  


Simcere Pharma (2096 HK): Proposed Spin-Off Will Unlock Value and Open Funding Avenues for Zaiming

Jiangsu Hengrui Pharmaceuticals / Equity Bottom-Up

Jiangsu Hengrui Pharmaceuticals (1276 HK)

<ul>
<li>
<a href="https://www.smartkarma.com/entities/jiangsu-hengrui-pharmaceuticals-co-ltd" target="_blank" data-smartkarma-citation="entities:44224:1" rel="noopener">Jiangsu Hengrui Pharmaceuticals (1276 HK)</a> received approval of Retlirafusp Injection from NMPA. It is first-line treatment of locally advanced unresectable, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma (PD-L1 positive).</li>
<li>There are no similar approved products for in China and abroad. Merck’s bintrafusp alfa has advanced to Phase III trials, while most other candidates are still in Phase I/II stages.</li>
<li>With Robust R&amp;D and future potential drug candidates under its belt, Jiangsu Hengrui continues to remain an attractive bet, with a long-term perspective.</li>
</ul>



Jiangsu Hengrui Pharmaceuticals (1276 HK) received approval of Retlirafusp Injection from NMPA. It is first-line treatment of locally advanced unresectable, recurrent or metastatic gastric and gastroesophageal junction adenocarcinoma (PD-L1 positive).
There are no similar approved products for in China and abroad. Merck’s bintrafusp alfa has advanced to Phase III trials, while most other candidates are still in Phase I/II stages.
With Robust R&amp;D and future potential drug candidates under its belt, Jiangsu Hengrui continues to remain an attractive bet, with a long-term perspective.


Jiangsu Hengrui (HK 1276): Begins 2026 On a Positive Note With Retlirafusp Approval; More to Follow

<ul>
<li>
<a href="https://www.smartkarma.com/entities/simcere-pharmaceutical-group" target="_blank" data-smartkarma-citation="entities:29186:1" rel="noopener">Simcere Pharmaceutical Group (2096 HK)</a> entered into a license agreement with Vigonvita Life Science Co. Ltd in respect of new indications (RSV and HMPV) of VV116 (Deuterated Remdesivir Hydrobromide).</li>
<li>There is no innovative small molecule antiviral drug approved for RSV infection globally. The development of effective RSV treatment represents a huge unmet medical need worldwide.</li>
<li>The licensing deals signed over the last few months alongside strong innovative drug portfolio, approvals and strong future pipeline makes it a bullish case.</li>
</ul>



Simcere Pharmaceutical Group (2096 HK) entered into a license agreement with Vigonvita Life Science Co. Ltd in respect of new indications (RSV and HMPV) of VV116 (Deuterated Remdesivir Hydrobromide).
There is no innovative small molecule antiviral drug approved for RSV infection globally. The development of effective RSV treatment represents a huge unmet medical need worldwide.
The licensing deals signed over the last few months alongside strong innovative drug portfolio, approvals and strong future pipeline makes it a bullish case.


Simcere Pharma (2096 HK): Agreement With Vigonvita Positive, Pipeline and Approvals Key Strength

China

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a pharmaceutical company. Through its subsidiaries, the Company manufactures genetic medicines, Chinese traditional medicines, diagnostic products, and medical instruments, provides technology, marketing, and advertising services, as well as invests in import and export trading.

Shanghai Fosun Pharmaceutical (Group) (600196 CH)

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Shanghai Fosun Pharmaceutical (Group) (600196 CH)

Aequitas: Mirxes IPO Lockup - 44% of the Stock up for Lockup Release, with a Lot of CCASS Movement

Mirxes Holding (2629 HK) raised around US$130m in its Hong Kong listing in May 2025. The lockup on its pre-IPO shareholders is set to expire soon.

Sumeet Singh

CSPC Pharma (1093 HK): AstraZeneca Collaboration Good, Impact Might Be Short Lived Given Competition

CSPC Pharma partnered with AstraZeneca for long-acting peptide medicines, receiving substantial upfront and milestone payments. Weight loss drug...

Tina Banerjee

Simcere Pharma (2096 HK): Proposed Spin-Off Will Unlock Value and Open Funding Avenues for Zaiming

Simcere Pharma plans to spin-off and separately list shares of subsidiary Simcere Zaiming, unlocking value and providing separate access to funds...

Tina Banerjee

Jiangsu Hengrui (HK 1276): Begins 2026 On a Positive Note With Retlirafusp Approval; More to Follow

Jiangsu Hengrui Pharmaceuticals receives approval for new cancer treatment. Gradually positioning itself as a strong player in the market with...

Tina Banerjee

Simcere Pharma (2096 HK): Agreement With Vigonvita Positive, Pipeline and Approvals Key Strength

Simcere inked exclusive outlicensing agreement with Ipsen Pharma for the development, manufacturing, and commercialization of SIM0613, a LRRC15...

Tina Banerjee

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)

Aequitas: Mirxes IPO Lockup - 44% of the Stock up for Lockup Release, with a Lot of CCASS Movement

Mirxes Holding (2629 HK) raised around US$130m in its Hong Kong listing in May 2025. The lockup on its pre-IPO shareholders is set to expire soon.

Sumeet Singh

CSPC Pharma (1093 HK): AstraZeneca Collaboration Good, Impact Might Be Short Lived Given Competition

​CSPC Pharma partnered with AstraZeneca for long-acting peptide medicines, receiving substantial upfront and milestone payments. Weight loss drug...

Tina Banerjee

Simcere Pharma (2096 HK): Proposed Spin-Off Will Unlock Value and Open Funding Avenues for Zaiming

​Simcere Pharma plans to spin-off and separately list shares of subsidiary Simcere Zaiming, unlocking value and providing separate access to funds...

Tina Banerjee

Jiangsu Hengrui (HK 1276): Begins 2026 On a Positive Note With Retlirafusp Approval; More to Follow

​Jiangsu Hengrui Pharmaceuticals receives approval for new cancer treatment. Gradually positioning itself as a strong player in the market with...

Tina Banerjee

Simcere Pharma (2096 HK): Agreement With Vigonvita Positive, Pipeline and Approvals Key Strength

Simcere inked exclusive outlicensing agreement with Ipsen Pharma for the development, manufacturing, and commercialization of SIM0613, a LRRC15...

Tina Banerjee

CSPC Pharma partnered with AstraZeneca for long-acting peptide medicines, receiving substantial upfront and milestone payments. Weight loss drug...

Simcere Pharma plans to spin-off and separately list shares of subsidiary Simcere Zaiming, unlocking value and providing separate access to funds...

Jiangsu Hengrui Pharmaceuticals receives approval for new cancer treatment. Gradually positioning itself as a strong player in the market with...